Introduction: A living cell-based treatment (LCT; Apligraf®) consisting of human neonatal allogeneic keratinocytes and fibroblasts embedded in an extracellular matrix has been shown through multiple randomized controlled multicenter trials to improve the rate of healing of venous leg ulcers and diabetic foot ulcers. More limited data supports the notion that LCT can be used to improve the quality of healing by secondary intention. However, secondary intention healing in both cutaneous and mucosal environments is normally associated with prolonged time to healing, inflammation, pain and scar formation. Our hypothesis was that LCT could be used to modulate and improve the trajectory of secondary intention healing. We were particularly interested in the type and quality of tissue that could be produced.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.